These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7022510)

  • 21. Antithrombotic effects of KP-10614, a novel and stable prostacyclin (PGI2) analog.
    Kanayama T; Kimura Y; Iseki K; Hayashi Y; Tamao Y; Mizogami S
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1210-7. PubMed ID: 1702154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous infusion of prostacyclin sodium in man: clinical effects and influence on platelet adenosine diphosphate sensitivity and adenosine 3':5'-cyclic monophosphate levels.
    Data JL; Molony BA; Meinzinger MM; Gorman RR
    Circulation; 1981 Jul; 64(1):4-12. PubMed ID: 6263515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet sensitivity to adenosine diphosphate and to prostacyclin in diabetic patients.
    Onodera H; Hirata T; Sugawara H; Sugai K; Yoda B; Toyota T; Goto Y
    Tohoku J Exp Med; 1982 Aug; 137(4):423-8. PubMed ID: 6750843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological evaluation of 5-(Z,E)-13,14-didehydro-20-methyl-carboprostacyclin (FCE 22509).
    Ceserani R; Grossoni M; Ukmar G; Colombo M; Mongelli N
    Prostaglandins Leukot Med; 1986 Mar; 21(3):231-45. PubMed ID: 3517883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet function studies during and after infusions of ZK 36374, a stable prostacyclin analogue, to healthy volunteers.
    Yardumian DA; Mackie IJ; Brennan EC; Bull H; Machin SJ
    Haemostasis; 1986; 16(1):20-6. PubMed ID: 2422095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of intravenous infusions of prostaglandin D2 in man.
    Heavey DJ; Lumley P; Barrow SE; Murphy MB; Humphrey PP; Dollery CT
    Prostaglandins; 1984 Dec; 28(6):755-67. PubMed ID: 6596653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man.
    Krause W; Krais T
    Eur J Clin Pharmacol; 1986; 30(1):61-8. PubMed ID: 2423342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets.
    Hawiger J; Parkinson S; Timmons S
    Nature; 1980 Jan; 283(5743):195-7. PubMed ID: 6985716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparin neutralization of PGI2: effects upon platelets.
    Saba HI; Saba SR; Blackburn CA; Hartmann RC; Mason RG
    Science; 1979 Aug; 205(4405):499-501. PubMed ID: 377493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation.
    Aiken JW; Gorman RR; Shebuski RJ
    Prostaglandins; 1979 Apr; 17(4):483-94. PubMed ID: 111306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological profile of a novel carbacyclin derivative with high metabolic stability and oral activity in the rat.
    Stürzebecher S; Haberey M; Müller B; Schillinger E; Schröder G; Skuballa W; Stock G; Vorbrüggen H; Witt W
    Prostaglandins; 1986 Jan; 31(1):95-109. PubMed ID: 3513260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical prostacyclin (PGI2) inhibits platelet aggregation in pial venules of the mouse.
    Rosenblum WI; El-Sabban F
    Stroke; 1979; 10(4):399-401. PubMed ID: 388737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Platelet sensitivity to prostacyclin (PGI2) in patients with juvenile-onset diabetes mellitus (author's transl)].
    Klein K; Sinzinger H; Schernthaner G; Silberbauer K; Prager R
    Wien Klin Wochenschr; 1981 Jul; 93(14):460-2. PubMed ID: 7023074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostacyclin (PGI2) inhibits the development in human platelets of ADP and arachidonic acid-induced shape change and procoagulant activity.
    Ehrman ML; Jaffe EA
    Prostaglandins; 1980 Dec; 20(6):1103-16. PubMed ID: 7010448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of prostacyclin (PGT2) on platelet behaviour. Thrombus formation in vivo and bleeding time.
    Ubatuba FB; Moncada S; Vane JR
    Thromb Haemost; 1979 Apr; 41(2):425-35. PubMed ID: 382434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerance and pharmacology of ciprostene, a stable epoprostenol (prostacyclin) analogue in humans.
    Linet OI; Nishizawa EE; Schaub RG; VanderLugt JT; Greenwald CA
    J Clin Pharmacol; 1986 Feb; 26(2):131-40. PubMed ID: 3005377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response.
    Skrinska VA; Lucas FV; Chisolm GM; Hesse BL
    J Lab Clin Med; 1986 Mar; 107(3):187-93. PubMed ID: 3512745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood.
    Saniabadi AR; Belch JJ; Lowe GD; Barbenel JC; Forbes CD
    Haemostasis; 1987; 17(3):147-53. PubMed ID: 2440771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
    Beretz A; Stierle A; Anton R; Cazenave JP
    Biochem Pharmacol; 1982 Nov; 31(22):3597-600. PubMed ID: 6295405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pulmonary and antiaggregatory effects of prostacyclin after inhalation and intravenous infusion.
    Burghuber OC; Silberbauer K; Haber P; Sinzinger H; Elliott M; Leithner C
    Respiration; 1984; 45(4):450-4. PubMed ID: 6382493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.